Pharmala Biotech Holdings Inc.
MDMA
CNSX
| 11/30/2025 | 08/31/2025 | 05/31/2025 | 02/28/2025 | 11/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 540.70K | 434.50K | 300.00K | 310.00K | 249.60K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 540.70K | 434.50K | 300.00K | 310.00K | 249.60K |
| Cost of Revenue | 63.20K | 38.20K | -95.50K | -99.40K | -106.00K |
| Gross Profit | 477.40K | 396.20K | 395.40K | 409.20K | 355.50K |
| SG&A Expenses | 1.57M | 1.57M | 1.46M | 1.50M | 1.10M |
| Depreciation & Amortization | 83.60K | 83.80K | 79.20K | 70.10K | 61.50K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.90M | 1.87M | 1.64M | 1.60M | 1.14M |
| Operating Income | -1.36M | -1.43M | -1.34M | -1.29M | -894.70K |
| Income Before Tax | -1.50M | -1.55M | -1.45M | -1.38M | -981.00K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.50 | -1.55 | -1.45 | -1.38 | -0.98 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.50M | -1.55M | -1.45M | -1.38M | -981.00K |
| EBIT | -1.36M | -1.43M | -1.34M | -1.29M | -894.70K |
| EBITDA | -1.32M | -1.38M | -1.30M | -1.24M | -846.50K |
| EPS Basic | -0.01 | -0.02 | -0.01 | -0.01 | -0.01 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.01 | -0.02 | -0.01 | -0.01 | -0.01 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 414.11M | 398.18M | 390.88M | 374.74M | 359.89M |
| Average Diluted Shares Outstanding | 414.11M | 398.18M | 390.88M | 374.74M | 359.89M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |